A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males

ConclusionCT-P16 demonstrated pharmacokinetic equivalence to EU-bevacizumab and US-bevacizumab. Safety and immunogenicity profiles were similar for CT-P16, EU-bevacizumab, and US-bevacizumab. These data support the further clinical evaluation of CT-P16 as a bevacizumab biosimilar.Clinical Trials RegistrationNCT03247673.

http://link.springer.com/10.1007/s40259-019-00340-x

Source: BioDrugs - March 8, 2019 Category: Drugs & Pharmacology Source Type: research